Ducommun heads into its May 7 Q1 print carrying the sharpest short-interest build the stock has seen in months, set against a Street that has just lifted its targets and a price that — despite a 14.6% monthly gain — slipped 3.3% on the final session of the week.
The short-interest story is the standout this week. Estimated SI roughly doubled over the past month, from about 2.1% of the free float in mid-March to 4.5% by April 28 — a 108% rise in reported shares short. The most abrupt step came around April 22-24, when the borrow jumped in a single session from 3.2% to 4.4% of float and has held there. That single-week move of roughly 42% is difficult to attribute to anything other than a deliberate pre-earnings positioning call. Days to cover remain modest at 1.2 days, so this isn't a trapped-short situation — it looks more like active initiation ahead of results. Yet borrow conditions remain loose: cost to borrow is only 0.59% annualised (up 17% on the week but historically cheap), and availability is ample, suggesting the lending market has absorbed the new demand without strain.
Options tell a different story. Call positioning dominates thoroughly, with the put/call ratio at just 0.07 — nearly half a standard deviation below its already-low 20-day average of 0.09 and close to the 52-week low of 0.04. The short score has nudged up to 38.3 from 33.9 four weeks ago, but the 52-week cap is 5.8% utilisation versus a current reading near 2.6% — there is no evidence of a squeeze setup. The divergence between rising shorts and persistently call-heavy options flow is the tension worth watching: one cohort is buying insurance on the downside, another is still positioned for upside.
The Street is firmly constructive. Goldman Sachs lifted its target to $151 on April 20, maintaining Buy — the most recent bellwether action. RBC (Outperform, $150) and Citi (Buy, $141) have all nudged targets higher this year in a steady pattern of upward revisions. The consensus mean target of $147 implies only modest upside from the $138.40 close, just 2.4% return potential — so the Street is not betting on a re-rating so much as confirming the current range. The PE has expanded to 31x, up five turns over the past month, and the EV/EBITDA multiple of 15.4x is broadly in line with the aerospace and defense peer group. RSI14 at 61 reflects positive but not overbought momentum on a YTD gain of 49%.
Most close peers sold off harder over the week. ATRO fell 7.8% and LOAR dropped 9.8%, while DCO added 1.2%, suggesting some relative resilience or idiosyncratic buying ahead of its own result. AIR shed 5.2% and CW lost 2.1%. The peer weakness is worth noting because it underscores how much of DCO's recent outperformance has been stock-specific rather than a sector tailwind.
The cluster of insider sales in early March — spanning the CEO, CFO, General Counsel, and multiple senior VPs, totalling over $3.5 million in aggregate — was conducted near $130-$139 and is now comfortably in the money at $138. None of the sales were enormous as a percentage of holdings, and the 90-day net figure includes a significant executive stake (Stephen Oswald still holds 2.9% of shares), but the breadth of the selling across the C-suite at those levels is context worth keeping in mind when the print arrives.
The May 7 release is now the focal event: the February print saw a 1-day drop of 2.5% followed by a 2.7% recovery over the ensuing week, which suggests the stock has historically digested mixed first reactions. The question heading into next week is whether the sharp shorts-build from late April represents a well-informed fade of the recent rally — or a position that gets washed out if Ducommun again beats modestly and guides in line.
See the live data behind this article on ORTEX.
Open DCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
